Novartis | NVS - L'Utile Operativo





L'Utile Operativo Cambiamento Data
AbbVie USD 6.88B 156M 2026-09
Amgen USD 4.68B 65M 2026-09
AstraZeneca USD 4.66B 1.5B 2026-09
Bausch Health Companies USD 993M 217M 2026-09
Biogen USD 419.5M 663.3M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Canopy Growth CAD -17.58M 9.9M 2026-06
Corcept Therapeutics USD 114.72M 73.42M 2026-09
Drreddys Laboratories INR 12.81B 11.98B 2026-09
Eli Lilly USD 12.46B 2.68B 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.86B 251M 2026-09
Glaxosmithkline GBP 2.13B 166M 2026-09
J&J USD 6.47B 1B 2026-09
Merck USD 7.33B 6.49B 2026-09
Novartis USD 5.14B 392M 2026-09
Novartis USD 1.84B 2.39B 2026-09
Pacira USD 2.57B 2.56B 2026-09
Perrigo USD 27.2M 3.7M 2026-09
Pfizer USD 662M 5M 2026-09
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 52.52M 22.97M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 4.72B 2.34B 2026-09
Sanofi EUR 2.38B 115M 2026-06
Supernus Pharmaceuticals USD -21.04M 14.21M 2026-06
Zoetis USD 1.03B 88M 2026-09